Testosterone therapy in diabetes and pre‐diabetes

Type 2 diabetes mellitus and pre‐diabetes are associated with reduced circulating testosterone levels. However, the role of testosterone replacement therapy in these patients is still conflicting.

[1]  Aline Mânica,et al.  The purinergic signalling and inflammation in the pathogenesis and progression of diabetes: key factors and therapeutic targets , 2022, Inflammation Research.

[2]  M. Maggi,et al.  Testosterone Therapy With a Man With Equivocal Testosterone Levels. , 2022, The journal of sexual medicine.

[3]  E. Platz,et al.  Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer , 2022, Cancer Causes & Control.

[4]  L. Vignozzi,et al.  Androgens and male sexual function. , 2022, Best practice & research. Clinical endocrinology & metabolism.

[5]  E. Mannucci,et al.  The Role of testosterone treatment in patients with metabolic disorders , 2021, Expert review of clinical pharmacology.

[6]  S. Arver,et al.  Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men , 2021, The aging male : the official journal of the International Society for the Study of the Aging Male.

[7]  V. Gebski,et al.  Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. , 2021, The lancet. Diabetes & endocrinology.

[8]  E. Rapizzi,et al.  Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men , 2020, Journal of Endocrinological Investigation.

[9]  V. Triggiani,et al.  Critical evaluation of different available guidelines for late‐onset hypogonadism , 2020, Andrology.

[10]  G. Doros,et al.  Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study , 2020, International Journal of Obesity.

[11]  M. Maggi,et al.  Testosterone Therapy: What We Have Learned From Trials. , 2020, The journal of sexual medicine.

[12]  A. Cheung,et al.  Late‐onset hypogonadism: metabolic impact , 2020, Andrology.

[13]  E. Sarchielli,et al.  Treatment of Functional Hypogonadism Besides Pharmacological Substitution , 2019, The world journal of men's health.

[14]  M. Maggi,et al.  Metabolically healthy and unhealthy obesity in erectile dysfunction and male infertility , 2019, Expert review of endocrinology & metabolism.

[15]  Xiaotian Liu,et al.  Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: The Henan Rural Cohort Study , 2019, Diabetes/metabolism research and reviews.

[16]  F. Guaraldi,et al.  Impact of Metabolically Healthy Obesity in Patients with Andrological Problems. , 2019, The journal of sexual medicine.

[17]  U. Hostalek.  Global epidemiology of prediabetes - present and future perspectives , 2019, Clinical Diabetes and Endocrinology.

[18]  F. Montorsi,et al.  Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction , 2019, International journal of impotence research.

[19]  W. Garvey,et al.  Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study , 2019, Diabetes Care.

[20]  F. Azizi,et al.  The association between serum total testosterone and progression of hyperglycemia: a 15‐year prospective cohort study , 2019, Andrology.

[21]  Xiao Li,et al.  Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis , 2019, The aging male : the official journal of the International Society for the Study of the Aging Male.

[22]  Yan-hui Lu,et al.  Testosterone level in aging male with different glucose tolerance state and its association with osteocalcin , 2018, The aging male : the official journal of the International Society for the Study of the Aging Male.

[23]  Xiao Li,et al.  Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review , 2018, World Journal of Urology.

[24]  N. Oliver,et al.  Testosterone therapy for sexual dysfunction in men with Type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[25]  M. Maggi,et al.  The safety of available treatments of male hypogonadism in organic and functional hypogonadism , 2018, Expert opinion on drug safety.

[26]  E. Mannucci,et al.  Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. , 2017, European urology.

[27]  Yingli Lu,et al.  Low Sex Hormone-Binding Globulin Levels Associate with Prediabetes in Chinese Men Independent of Total Testosterone , 2016, PloS one.

[28]  A. Aversa,et al.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies , 2016, Journal of Endocrinological Investigation.

[29]  B. Walker,et al.  Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men , 2016, The Journal of clinical endocrinology and metabolism.

[30]  A. Aversa,et al.  THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. , 2016, European journal of endocrinology.

[31]  E. Mannucci,et al.  Obesity and late-onset hypogonadism , 2015, Molecular and Cellular Endocrinology.

[32]  P. Dandona,et al.  Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes , 2015, Diabetes Care.

[33]  E. Baldi,et al.  Metabolic syndrome-associated sperm alterations in an experimental rabbit model: Relation with metabolic profile, testis and epididymis gene expression and effect of tamoxifen treatment , 2015, Molecular and Cellular Endocrinology.

[34]  P. Piątkiewicz,et al.  Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population , 2015, The aging male : the official journal of the International Society for the Study of the Aging Male.

[35]  M. Maggi,et al.  Injectable testosterone undecanoate for the treatment of hypogonadism , 2014, Expert opinion on pharmacotherapy.

[36]  E. Sarchielli,et al.  Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit , 2014, Molecular and Cellular Endocrinology.

[37]  E. Sarchielli,et al.  Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits , 2014, Molecular and Cellular Endocrinology.

[38]  Kun-jie Wang,et al.  Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials , 2013, Asian journal of andrology.

[39]  F. Jaw,et al.  Prediabetes Is Associated with an Increased Risk of Testosterone Deficiency, Independent of Obesity and Metabolic Syndrome , 2013, PloS one.

[40]  G. Forti,et al.  The identification of prediabetes condition with ARIC algorithm predicts long-term CV events in patients with erectile dysfunction. , 2013, The journal of sexual medicine.

[41]  E. Sarchielli,et al.  Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. , 2012, The Journal of endocrinology.

[42]  M. Carini,et al.  Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  Wolfgang Rathmann,et al.  Prediabetes: a high-risk state for diabetes development , 2012, The Lancet.

[44]  G. Balercia,et al.  Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. , 2012, The journal of sexual medicine.

[45]  M. Carini,et al.  Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. , 2012, The Journal of endocrinology.

[46]  A. Lenzi,et al.  Type 2 diabetes mellitus and testosterone: a meta-analysis study. , 2011, International journal of andrology.

[47]  A. Silman,et al.  Identification of late-onset hypogonadism in middle-aged and elderly men. , 2010, The New England journal of medicine.

[48]  J. Holst,et al.  Sex Steroids Affect Triglyceride Handling, Glucose-Dependent Insulinotropic Polypeptide, and Insulin Sensitivity , 2010, Diabetes Care.

[49]  A. Silman,et al.  Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. , 2010, The Journal of clinical endocrinology and metabolism.

[50]  G. Forti,et al.  Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? , 2009, International journal of andrology.

[51]  Hang Lee,et al.  Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. , 2007, The Journal of clinical endocrinology and metabolism.

[52]  G. Balercia,et al.  Psychobiological correlates of delayed ejaculation in male patients with sexual dysfunctions. , 2006, Journal of andrology.

[53]  E. Ding,et al.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. , 2006, JAMA.

[54]  Heejung Bang,et al.  Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. , 2005, Diabetes care.

[55]  V. Marks,et al.  Differences in pituitary and testicular function between diabetic patients on insulin and oral anti-diabetic agents , 1978, Diabetologia.

[56]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[57]  M. Charles,et al.  Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. , 1997, The Journal of clinical endocrinology and metabolism.

[58]  J. Meunier,et al.  Pituitary-testicular axis in diabetic men with and without sexual impotence. , 1978, Diabete & metabolisme.